498 related articles for article (PubMed ID: 28187946)
1. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
[TBL] [Abstract][Full Text] [Related]
2. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
3. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T-cell therapies for multiple myeloma.
Mikkilineni L; Kochenderfer JN
Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
[TBL] [Abstract][Full Text] [Related]
5. A chimeric antigen receptor-based cellular safeguard mechanism for selective
Svec M; Dötsch S; Warmuth L; Trebo M; Fräßle S; Riddell SR; Jäger U; D'Ippolito E; Busch DH
Front Immunol; 2023; 14():1268698. PubMed ID: 38274808
[TBL] [Abstract][Full Text] [Related]
6. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.
Sheih A; Voillet V; Hanafi LA; DeBerg HA; Yajima M; Hawkins R; Gersuk V; Riddell SR; Maloney DG; Wohlfahrt ME; Pande D; Enstrom MR; Kiem HP; Adair JE; Gottardo R; Linsley PS; Turtle CJ
Nat Commun; 2020 Jan; 11(1):219. PubMed ID: 31924795
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Kochenderfer JN; Yu Z; Frasheri D; Restifo NP; Rosenberg SA
Blood; 2010 Nov; 116(19):3875-86. PubMed ID: 20631379
[TBL] [Abstract][Full Text] [Related]
8. Depletion of T cells
Klopp A; Schreiber S; Kosinska AD; Pulé M; Protzer U; Wisskirchen K
Front Immunol; 2021; 12():734246. PubMed ID: 34691041
[TBL] [Abstract][Full Text] [Related]
9. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
Pennell CA; Barnum JL; McDonald-Hyman CS; Panoskaltsis-Mortari A; Riddle MJ; Xiong Z; Loschi M; Thangavelu G; Campbell HM; Storlie MD; Refaeli Y; Furlan SN; Jensen MC; Kean LS; Miller JS; Tolar J; Osborn MJ; Blazar BR
Mol Ther; 2018 Jun; 26(6):1423-1434. PubMed ID: 29735365
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M; Oporto-Espuelas M; Burridge S; Chu J; Farish S; Hedges E; Ware K; Williams L; Young L; Alajangi R; Ancliff P; Bartram J; Bonney D; Chenchara L; Chiesa R; Cugno C; Hodby K; Jalowiec KA; Lazareva A; Lucchini G; Mirci-Danicar OC; Mullanfiroze K; Pavasovic V; Rao A; Rao K; Riley L; Samarasinghe S; Shenton G; Silva J; Vora A; Hough R; Amrolia PJ; Ghorashian S
Blood Adv; 2024 Apr; 8(8):1959-1963. PubMed ID: 37820111
[No Abstract] [Full Text] [Related]
11.
Pfeiffer A; Thalheimer FB; Hartmann S; Frank AM; Bender RR; Danisch S; Costa C; Wels WS; Modlich U; Stripecke R; Verhoeyen E; Buchholz CJ
EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224381
[TBL] [Abstract][Full Text] [Related]
12. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
Barrett DM; Liu X; Jiang S; June CH; Grupp SA; Zhao Y
Hum Gene Ther; 2013 Aug; 24(8):717-27. PubMed ID: 23883116
[TBL] [Abstract][Full Text] [Related]
13. Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19.
Fioretti S; Matson CA; Rosenberg KM; Singh NJ
Cancer Immunol Immunother; 2023 Jan; 72(1):257-264. PubMed ID: 35753001
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19
Marin D; Li Y; Basar R; Rafei H; Daher M; Dou J; Mohanty V; Dede M; Nieto Y; Uprety N; Acharya S; Liu E; Wilson J; Banerjee P; Macapinlac HA; Ganesh C; Thall PF; Bassett R; Ammari M; Rao S; Cao K; Shanley M; Kaplan M; Hosing C; Kebriaei P; Nastoupil LJ; Flowers CR; Moseley SM; Lin P; Ang S; Popat UR; Qazilbash MH; Champlin RE; Chen K; Shpall EJ; Rezvani K
Nat Med; 2024 Mar; 30(3):772-784. PubMed ID: 38238616
[TBL] [Abstract][Full Text] [Related]
15. Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells.
Eugene-Norbert M; Cuffel A; Riou G; Jean L; Blondel C; Dehayes J; Bisson A; Giverne C; Brotin E; Denoyelle C; Poulain L; Boyer O; Martinet J; Latouche JB
J Immunol Methods; 2024 Feb; 525():113603. PubMed ID: 38147898
[TBL] [Abstract][Full Text] [Related]
16. Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation.
Su Q; Yao J; Farooq MA; Ajmal I; Duan Y; He C; Hu X; Jiang W
Cells; 2024 Mar; 13(6):. PubMed ID: 38534399
[TBL] [Abstract][Full Text] [Related]
17. Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.
Pajarillo R; Paruzzo L; Carturan A; Ugwuanyi O; White G; Guruprasad P; Ballard HJ; Patel RP; Zhang Y; Lee YG; Hong SJA; Dittami GM; Ruella M
Cytotherapy; 2024 May; 26(5):506-511. PubMed ID: 38483365
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Drent E; Poels R; Mulders MJ; van de Donk NWCJ; Themeli M; Lokhorst HM; Mutis T
PLoS One; 2018; 13(5):e0197349. PubMed ID: 29847570
[TBL] [Abstract][Full Text] [Related]
19. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
Pang Y; Hou X; Yang C; Liu Y; Jiang G
Mol Cancer; 2018 May; 17(1):91. PubMed ID: 29769134
[TBL] [Abstract][Full Text] [Related]
20. A New Frontier: CD19 Chimeric Antigen Receptor T-Cell Therapy.
Alcocer Alkureishi L; Hageman JR
Pediatr Ann; 2024 May; 53(5):e157-e158. PubMed ID: 38700917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
